GSK Total Liabilities 2010-2024 | GSK

GSK total liabilities for the quarter ending June 30, 2024 were $55.906B, a 5.61% decline year-over-year.

  • GSK total liabilities for 2023 were $57.481B, a 7.15% decline from 2022.
  • GSK total liabilities for 2022 were $61.907B, a 22.06% decline from 2021.
  • GSK total liabilities for 2021 were $79.427B, a 3.75% increase from 2020.

GSK Total Liabilities 2010-2024 | GSK

  • GSK total liabilities for 2023 were $57.481B, a 7.15% decline from 2022.
  • GSK total liabilities for 2022 were $61.907B, a 22.06% decline from 2021.
  • GSK total liabilities for 2021 were $79.427B, a 3.75% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$178.6B
Regeneron Pharmaceuticals (REGN)$127.1B
Vertex Pharmaceuticals (VRTX)$125.3B
Gilead Sciences (GILD)$103.1B
Bristol Myers Squibb (BMY)$99.6B
CSL (CSLLY)$97.7B
Alnylam Pharmaceuticals (ALNY)$34.1B
Argenex SE (ARGX)$32.2B
BioNTech SE (BNTX)$29.3B
Biogen (BIIB)$28.5B
Moderna (MRNA)$26.2B
Illumina (ILMN)$20.6B
BeiGene (BGNE)$19.3B
Genmab (GMAB)$17.8B
BioMarin Pharmaceutical (BMRN)$16.1B
Vaxcyte (PCVX)$12.9B
Insmed (INSM)$12.8B
Incyte (INCY)$12.2B
Exact Sciences (EXAS)$12.1B
Sarepta Therapeutics (SRPT)$11.9B
Bio-Techne Corp (TECH)$11.8B
QIAGEN (QGEN)$10.6B
Legend Biotech (LEGN)$9.2B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.8B
Intra-Cellular Therapies (ITCI)$8B
Halozyme Therapeutics (HALO)$7.9B
Repligen (RGEN)$7.8B
Exelixis (EXEL)$7.5B
Viking Therapeutics (VKTX)$7.4B